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Central nervous system (CNS) relapse is a critical issue while treating Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph-positive ALL). A 58-year-old woman with Ph-positive ALL who relapsed after bone
marrow transplantation for meningeal leukemia was treated with high-dose methotrexate, which resulted in
remission. She underwent allogeneic cord blood transplantation followed by reduced intensity conditioning
chemotherapy with imatinib; however, she experienced CNS relapse and developed an extramedullary mass on
the right side of the temporal region. We treated 40 mg of dasatinib once daily, which had to be temporarily
discontinued because she developed grade 2 pleural effusion and grade 2 hematemesis. After reinitiation of
dasatinib, the extramedullary mass disappeared and meningeal leukemia ameliorated almost immediately. With
40 mg dasatinib administered once daily, its trough level and cerebrospinal fluid (CSF) concentration were 32 ng/mL
and below the sensitivity threshold of 1 ng/mL, respectively. Treatment was continued, and the patient remained
in complete remission until she died of pneumonia 7 years after the initial diagnosis of ALL. Dasatinib can be an
effective treatment for Ph-positive ALL with CNS relapse. Although the concentration in the CSF seems low, it may
be sufficient to exert anti-leukemic effects in the human CNS.
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Philadelphia chromosome-positive acute lymphoblastic
leukemia (Ph-positive ALL) is a serious hematological
malignancy that usually requires combination chemo-
therapy to achieve complete remission. Patients with Ph-
positive ALL often develop resistance to chemotherapy,
which leads to relapse and death. Even with intensive
consolidation and maintenance therapies, many patients* Correspondence: taizo@med.kawasaki-m.ac.jp
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in any medium, provided the original work is pwho achieve remission relapse after a short period of
time. Previous studies on Ph-positive ALL patients re-
ported a median disease-free survival (DFS) and 3-year
DFS rate of 8.7 months and 24%, respectively, while the
5-year overall survival (OS) rate remained low at 24%–
34% (Yanada et al. 2009; Iida et al. 2004; Thomas et al.
2004). Adult ALL patients rarely present with meningeal
leukemia at initial diagnosis (only approximately 5% of
ALL patients), and central nervous system (CNS) relapse
occurs in 5%–10% patients who receive routine CNS-
directed prophylactic therapy (Lazarus et al. 2006; Pfeifer
et al. 2003). The outcome of patients with meningealn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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CNS-directed therapy (Lazarus et al. 2006). In recent
years, the oral tyrosine kinase inhibitors (TKIs) imatinib
and dasatinib have been prescribed for the treatment of
relapsed Ph-positive ALL after hematopoietic stem cell
transplantation (HSCT) (Ishida et al. 2010; Czyz et al.
2010; Millot et al. 2009; Takami et al. 2006). TKI com-
bined with conventional chemotherapy and incorporated
into the transplantation strategy has improved the long-
term survival of patients with Ph-positive ALL and has
allowed the de-escalation of chemotherapy. This com-
bination treatment strategy has prolonged DFS and OS
(Thyagu et al. 2012; Tanguy-Schmidt et al. 2013) beyond
the current rates. Dasatinib is an active agent in heavily
pretreated Ph-positive ALL patients, including those
who have undergone prior HSCT or those who have
been treated previously with imatinib-containing therapy
(Takami et al. 2006; Sakamaki et al. 2009; Ottmann et al.
2007; Tachibana et al. 2011). Dasatinib appears to reach
the cerebrospinal fluid (CSF) better than other TKIs ac-
cording to recent reports that claimed stabilization and
regression of CNS disease in a small series of patients
(Alimena et al. 2009; Porkka et al. 2008; Abdelhalim
et al. 2007). The CSF concentration of dasatinib after
oral administration in humans is poorly understood.
Here we describe the case of a Ph-positive ALL patient
who developed extramedullary relapse with CNS in-
volvement after imatinib-based treatment and subse-
quent HSCT. The patient exhibited a complete response
to dasatinib-based therapy, which resulted in long-term
survival. We also investigated the dasatinib concentra-
tions in this patient’s plasma and CSF.
Case description
A 58-year-old woman presented with loss of appetite
and general fatigue. Blood examination revealed marked
leukocytosis (37.6 × 109/L) with 81.5% lymphoblasts.
Bone marrow aspiration showed that 95% lymphoblastic
cells were positive for B-cell markers, including CD10,
CD19, CD34, and human leukocyte antigen (HLA)-DR,
while cytogenetic analysis reported a complex karyotype
including t(9;22) (q34;q11). Real-time quantitative poly-
merase chain reaction (RT-qPCR) detected 3.1 × 105
copies/μg of RNA p210 bcr-abl transcripts in the
marrow specimen. The patient was diagnosed with
Ph-positive precursor B-cell ALL in April 2005, when
imatinib-combined induction therapy was initiated
(Yanada et al. 2006).
She exhibited complete hematological and cytogenetic
responses, and bcr-abl transcripts were negative accord-
ing to RT-qPCR. In July 2005, after receiving high-dose
methotrexate (MTX) therapy as CNS prophylaxis, she
underwent bone marrow transplantation (BMT) using
an allogeneic bone marrow graft from an HLA-matchedsibling donor after a conditioning regimen with fludara-
bine (25 mg/m2/day for 5 days), busulfan (2mg/kg/day
for 2 days), and melphalan (80 mg/m2/day for 1 day).
Cyclosporine A and short-term MTX were used as
prophylaxis against graft-versus-host disease (GVHD).
The patient exhibited rapid and sustained engraftment,
with a neutrophil count higher than 0.5 × 109/L and a
platelet count higher than 50 × 109/L on day +16. How-
ever, 3 months after BMT, she relapsed with meningeal
leukemia, despite being treated with prophylactic intra-
thecal chemotherapy before BMT. She was subsequently
administered high-dose MTX therapy and 6 cycles of
MTX-based intrathecal chemotherapy. This regimen
eliminated lymphoblastic cells from her CSF, but 1.6 × 105
copies/μg of RNA p210 bcr-abl transcripts were still
detected in her marrow blood. In July 2006, she underwent
allogeneic cord blood transplantation (CBT) after a condi-
tioning regimen that included fludarabine (30 mg/m2/day
for 5 days), cytarabine (1.5 g/m2/day for 4 days), melphalan
(80 mg/m2/day for 1 day), and total body irradiation
with 4 Gy. Prophylaxis against GVHD was performed
with continuous infusion of tacrolimus.
Neutrophil engraftment was observed on day +18, but
acute GVHD was not observed. The patient developed a
limited type of chronic GVHD on day +165; neverthe-
less, she responded well to treatment with prednisolone.
However, 7 months after CBT, she relapsed again, devel-
oping meningeal leukemia accompanied by headache.
Imatinib and intrathecal chemotherapies were initiated
again, and whole-brain irradiation (24 Gy in total) was
added to her treatment regimen. She achieved remission,
and imatinib therapy was continued to prevent CNS re-
lapse. In April 2009, she again complained of headache,
and cranial magnetic resonance imaging revealed an
extramedullary mass on the right side of the temporal
region (Figure 1a).
The clinical course of the patient after relapse is shown
in Figure 2. Because of molecular resistance against ima-
tinib, the patient was treated with 100 mg of dasatinib
daily and was administered 2 cycles of intrathecal chemo-
therapy. While on dasatinib therapy, the patient, despite
receiving adequate supportive therapy, experienced grade
2 pleural effusion and grade 2 hematemesis according
to the National Cancer Institute Common Terminology
Criteria (NCI-CTC). Dasatinib was discontinued because
of these adverse events and reinitiated at a daily dose of 40
mg once she recovered. The extramedullary mass in her
temporal region disappeared (Figure 1b), and meningeal
leukemia was ameliorated almost immediately. During
the course of treatment, we investigated the dasatinib
concentrations in the patient’s plasma and CSF using
high-performance liquid chromatography coupled with
electrospray mass spectrometry (HPLC-MS) as described
previously (De Francia et al. 2009), albeit with some
Figure 1 MRI images of the head. a The extra-medullary mass of right temporal region before dasatinib treatment. b Forty-six days after initial
dasatinib treatment.
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dasatinib administered at a daily dose of 40 mg were 32
ng/mL and below the sensitivity threshold of 1 ng/mL, re-
spectively. Two months after the initiation of dasatinib
treatment, large granular lymphocytosis was observed in
the peripheral blood. These large granular lymphocytes
were CD3, CD8, CD56, and CD57 positive, and PCR re-
vealed an oligoclonal pattern of T-cell receptor gene re-
arrangement (data not shown). Until April 2011, the
patient remained in complete remission while taking 40
mg of dasatinib once daily; however, meningeal relapse
was revealed after close investigation of vertigo. Bone mar-
row examination showed the presence of 73 copies/μg ofFigure 2 Clinical course of the patient after diagnosis. X-axis shows mo
transplantation, CBT; allogeneic cord blood transplantation, cGVHD; chronicRNA p210 bcr-abl transcripts that were detected by RT-
qPCR. In addition, the lymphoblasts in her CSF harbored
an E255K ABL tyrosine kinase domain mutation, which is
known to be moderately resistant to both dasatinib and
nilotinib. On the basis of these results, we increased the
dose of dasatinib to 100 mg once daily and administered
one cycle of intrathecal chemotherapy. Three weeks after
the initiation of this treatment, the patient achieved
complete molecular remission in the bone marrow, and
lymphoblasts were undetectable in the CSF. Seven years
after the initial diagnosis of Ph-ALL, the patient died of
pneumonia. Until the time of her death, no evidence of
ALL recurrence was observed.nths after diagnosis. MTX; methotrexate, BMT; allogeneic bone marrow
graft versus host disease.
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CNS leukemia in patients with adult ALL is an uncom-
mon finding at initial diagnosis, affecting only approxi-
mately 5% of adult ALL patients. The 5-year OS rate of
these patients is lower than that of adult ALL patients
without CNS leukemia (29% vs 35%, respectively) (Lazarus
et al. 2006), and allogeneic HSCT is considered the only
curative option for these high-risk patients. However, re-
lapse remains the main cause of treatment failure. The
relapse rate of ALL patients with CNS leukemia who
achieve complete remission after allogeneic HSCT was re-
ported to be approximately 20%. A third of these patients
develop recurrent CNS leukemia if they relapse (Lazarus
et al. 2006). Although relapse after HSCT, particularly in
the CNS, is a major problem in the management of
Ph-positive ALL, effective therapeutic modalities for the
prevention of CNS relapse have not been established till
date. We observed the long-term survival of a patient with
Ph-positive ALL who had been treated with dasatinib for
relapsed meningeal leukemia after HSCT. Recently, en-
couraging reports for the treatment of Ph-positive ALL
with TKIs combined with chemotherapy or HSCT were
published (Ishida et al. 2010; Czyz et al. 2010; Millot et al.
2009; Takami et al. 2006; Thyagu et al. 2012; Tanguy-
Schmidt et al. 2013; Sakamaki et al. 2009; Ottmann et al.
2007; Tachibana et al. 2011; Abdelhalim et al. 2007;
Yanada et al. 2006; Nishii et al. 2007; Foa et al. 2011).
These reports suggest that dasatinib has strong anti-
leukemic activity against Ph-positive ALL, without the
prevention of donor hematopoiesis. Therefore, the use of
dasatinib as salvage therapy as well as prophylaxis against
relapse may be effective for Ph-positive ALL patients who
undergo allogeneic HSCT. Dasatinib has been shown to
be effective in the treatment of extramedullary leukemia
with CNS involvement in Ph-positive leukemia patients
(Alimena et al. 2009; Abdelhalim et al. 2007). Porkka et al.
reported that dasatinib exerts antitumor effects in a mouse
model of intracranial chronic myeloid leukemia and that
this drug has substantial benefits for patients with CNS
Ph-positive leukemia (Porkka et al. 2008). Dasatinib is
thought to penetrate the blood–brain barrier better than
imatinib, and this can result in dasatinib having better an-
tileukemic effects against CNS leukemia compared with
imatinib. In addition, dasatinib is active at lower concen-
trations (Porkka et al. 2008), and because the CSF has a
lower protein concentration compared with blood, this
drug is likely to exist as a free drug in the CNS. However,
few reports have examined the concentration of dasatinib
in human CSF samples (Porkka et al. 2008). The concen-
trations of dasatinib in our patient’s plasma and CSF were
32 ng/mL and less than the sensitivity threshold value, re-
spectively, when she was treated with a daily dose of 40
mg. The plasma concentration of 32 ng/mL at trough was
higher than that previously reported (Wang et al. 2013),and the discrepancy may be caused by the companion
agents administered to our patient, such as azoles, which
interfere with the metabolism of dasatinib. Previous stud-
ies reported that the dasatinib concentration in the CSF
varies between 5% and 28% of the plasma concentration
(Porkka et al. 2008). At the oral dasatinib dose of 140 mg
once daily or 70 mg twice daily, the CNS concentration
was undetectable in 87% patients, even if the samples were
collected in the absorptive phase, that is, at 1–4 h after
consuming the drug (Porkka et al. 2008). The undetectable
dasatinib concentration in the CNS fluid in our patient
may indicate a low concentration and an inadequate sam-
pling time at trough. Careful considerations for the timing
of sampling of CNS specimens should be made in future
studies. Taken together, these results suggest that the con-
centration of dasatinib in the CSF is usually maintained in
a low range, but this low concentration may be enough to
exert an anti-leukemic effect in the human CNS. The val-
idity of prophylactic or preemptive therapy with dasatinib
after allogeneic HSCT for Ph-positive ALL remains un-
clear. Till date, 2 studies, each with a small number of
cases, have reported encouraging results (Caocci et al.
2012; Teng et al. 2013), suggesting that dasatinib is highly
effective in preventing molecular relapse and eradicating
Ph-positive ALL after HSCT. At least, prophylactic and
preemptive dasatinib therapy should be considered for
high-risk patients who do not exhibit molecular responses
before or after HSCT and for patients who have extrame-
dullary leukemia with CNS involvement at the time of
diagnosis. Prospective and randomized studies aiming to
identify the appropriate dasatinib treatment regimen for
Ph-positive ALL after allogeneic HSCT are required.
Conclusion
Dasatinib can be an effective treatment for Ph-positive
ALL with CNS relapse.
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